Lsv Asset Management Incyte Corp Transaction History

Lsv Asset Management

$43.3 Billion
Q4 2024

A detailed history of Lsv Asset Management transactions in Incyte Corp stock. As of the latest transaction made, Lsv Asset Management holds 3,467,490 shares of INCY stock, worth $210 Million. This represents 0.55% of its overall portfolio holdings.

Number of Shares

3,467,490

Previous 2,923,410 18.61%

Holding current value

$210 Million

Previous $193 Million 23.94%

% of portfolio

0.55%

Previous 0.41%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$65.08 - $83.38 $35.4 Million - $45.4 Million	544,080 Added 18.61%	3,467,490 $240 Million
Q3 2024 Nov 12, 2024	BUY	$57.33 - $68.61 $8.8 Million - $10.5 Million	153,518 Added 5.54%	2,923,410 $193 Million
Q2 2024 Aug 06, 2024	BUY	$51.18 - $63.75 $773,585 - $963,581	15,115 Added 0.55%	2,769,892 $168 Million
Q1 2024 May 06, 2024	BUY	$56.55 - $66.59 $3.56 Million - $4.19 Million	62,950 Added 2.34%	2,754,777 $157 Million
Q4 2023 Feb 06, 2024	BUY	$52.16 - $64.19 $76.5 Million - $94.1 Million	1,465,792 Added 119.56%	2,691,827 $169 Million
Q3 2023 Nov 03, 2023	BUY	$57.77 - $65.93 $2.72 Million - $3.11 Million	47,100 Added 4.0%	1,226,035 $70.8 Million
Q2 2023 Aug 02, 2023	SELL	$60.95 - $75.51 $804,540 - $996,732	-13,200 Reduced 1.11%	1,178,935 $73.4 Million
Q1 2023 May 02, 2023	SELL	$70.23 - $86.01 $456,495 - $559,065	-6,500 Reduced 0.54%	1,192,135 $86.2 Million
Q4 2022 Feb 08, 2023	BUY	$67.18 - $84.11 $8.44 Million - $10.6 Million	125,570 Added 11.7%	1,198,635 $96.3 Million
Q3 2022 Nov 07, 2022	BUY	$66.18 - $82.86 $70.1 Million - $87.8 Million	1,059,965 Added 8091.34%	1,073,065 $71.5 Million
Q2 2022 Aug 10, 2022	BUY	$66.18 - $83.18 $866,958 - $1.09 Million	13,100 New	13,100 $995,000

Others Institutions Holding INCY

# of Institutions

707

Shares Held

189M

Call Options Held

909K

Put Options Held

489K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $13.5B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lsv Asset Management, based on Form 13F filings with the SEC.

News

Stay updated on Lsv Asset Management with notifications on news.

Account

Lsv Asset Management Incyte Corp Transaction History